CXCL1 and cancer: Topoisomerase inhibitors increase ROS levels in the cell [163], which leads to the activation of Janus tyrosine kinase 2 (JAK2)-signal transducer and activator of transcription 1 (STAT1) and thus elevated CXCL1 expression, as shown in experiments on many types of cancer [163].